Page 21 - Jonathan Arnold News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Catalent Agrees to Acquire Dry Powder Inhaler Spray Drying, Capsule Manufacturing, and Packaging Capabilities from Acorda Therapeutics Share Article Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced it has entered into a definitive agreement to acquire the manufacturing and packaging operations of Acorda Therapeutics, Inc., a developer of therapies to restore function and improve the lives of people with neurological disorders. The acquis...

Posted on 364 SK Capital Partners LP, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, today announced that funds it advises have signed a definitive agreement to acquire the Blow-Fill-Seal (“BFS”) Sterile Contract Development and Manufacturing Business (the “Business”) from Catalent Pharma Solutions, LLC. The acquisition of the Business, which will operate as a new independent company, is expected to close in April of 2021. The Business is a leading BFS sterile contract d...

SK Capital buying Catalent blow-fill-seal business Plastics News Report Catalent Pharma Solutions LLC Catalent Pharma Solutions LLC’s blow-fill-seal business has a single plant in Woodstock, Ill., molding polyethylene and polypropylene bottles, mostly for ophthalmic applications. Woodstock, Ill. — Private equity firm SK Capital Partners LP is making another purchase of a specialty plastics packaging company, buying Catalent Pharma Solutions LLC's blow-fill-seal business. The business has a single plant in Woodstock with 30 machines molding polyethylene and polypropylene bottles, mostly fo...

Jan 6, 2021 11:12am Pandemic manufacturing big shot Catalent is divesting its blow-fill-seal business to SK Capital in a bid to focus on other areas, like cell and gene therapy. (Catalent) New Jersey CDMO Catalent made waves last year as it inked one COVID-19 vaccine manufacturing deal after another, all the while continuing its push into cell and gene therapy. Now, the manufacturer is divesting one of its major business units as it looks to hone that focus on cutting-edge technology. Private equity firm SK Capital is ponying up an undisclosed sum to purchase Catalent’s blow-fill-seal ste...